ADC Introduction

Antibody-drug conjugates (ADCs) are targeted therapies that combine a monoclonal antibody with a potent drug payload through a chemical linker. ADCs are used to treat certain cancers, including solid tumors and hematologic malignancies. The antibody recognizes a specific antigen on target cells, while the linker and payload influence drug stability, delivery, and release. This targeted approach is designed to deliver potent therapeutic agents more selectively, although clinical efficacy and safety depend on the properties of each ADC.

An ADC consists of three key components: a target-specific monoclonal antibody, a drug payload, and a suitable linker. EirGenix supports ADC development and manufacturing through an integrated platform combining antibody development and production, linker-payload compatibility studies, and bioconjugation services in collaboration with strategic partners, including Formosa Laboratories.

End to End ADC/Bioconjugates Services

Monoclonal Antibody Development and Production

Antibodies, with their precise targeting capabilities, serve as essential carriers in the development of antibody-drug conjugates (ADCs). EirGenix offers end-to-end support for antibody development, encompassing both non-GMP and GMP-level manufacturing. Leveraging our Eirgenix/Formosa Laboratories service platform, we can perform early-stage compatibility studies across antibodies, intermediates, payloads, and linkers in parallel. This integrated approach ensures that all critical components are optimized for seamless and efficient process development, accelerating the path from concept to clinical-ready conjugates.

High Potency Chemicals

Formosa Laboratories, a strategic partner of EirGenix, is a global leader in high-potency drug manufacturing, supplying top-quality active pharmaceutical ingredients (APIs) to the US, EU, and other key markets worldwide. With a dedicated team of 58 chemists, 9 granted process patents, and 22 patents under review, Formosa combines cutting-edge innovation with robust manufacturing capabilities. Its advanced facilities—including 50–1,000 L stainless steel reactors, equally scaled chromatography columns, isolators (glove boxes), and 280 L falling film evaporators—support a production capacity of up to 2,000 L for high-potency APIs. These capabilities enable Formosa Laboratories to provide fully integrated services for the research, development, and manufacturing of high-potency compounds for ADCs, ensuring reliability, efficiency, and quality for clients across the globe.

Linkers

Linkers connect the monoclonal antibody to the drug payload and play a critical role in the stability and release characteristics of antibody-drug conjugates (ADCs). Linker selection helps maintain stability in circulation while enabling the intended payload release mechanism after delivery to target cells. Depending on the ADC design, both cleavable and non-cleavable linkers may be used. EirGenix works with linker development partners and Formosa Laboratories to integrate antibody, linker, and payload capabilities, supporting ADC development and manufacturing projects.